Feature Latest Stories
The reduction of breast cancer risk with 5 years of tamoxifen does not outweigh the lack of a mortality benefit, according to J. Michael Dixon, MD, OBE, who shared his view in a session at the 32nd Annual Miami Breast Cancer Conference.
Watch Full Video: Dr. Eric D. Hal, MD: Diagnostic accuracy of a defined Immunophenptypic and molecular genetic approach for peripheral T/NK-call lymphomas View Now >>
In this segment, the panelists discuss RAS testing for patients with colorectal cancer. View Now >>
Panelists discuss some of the key biomarker tests that can aid in making a prognosis and guiding treatment choices. View Now >>